CEACAM5 and microtia: Compared to those with normal CEA levels, abnormally high serum CEA levels were linked to a 125% increased risk of cancer-specific mortality in MA patients (HR ═ 2.25, 95% CI ═ 2.01–2.52, P < 0.001) and a 47% increased risk in SRCC patients.